The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course
Abstract
Introduction Fabry disease is an X-linked sphingolipidosis caused by complete or partial deficiency of the glycohydrolase α-galactosidase A (α-gal A) (4). The enzyme deficiency results in accumulation of globotriaosylceramide (Gb3, also known as ceramide trihexoside), as well as digalactosyl ceramide and blood group B, B1, and P1 glycolipids in the lysosomes of vascular endothelial, smooth muscle, epithelial, and ganglion cells. The metabolic defect causes a painful neuropathy, angiokeratomas, cardiac and cerebrovascular injury, and renal failure. Hemizygous males usually experience multisystem involvement with symptoms beginning in childhood or infancy, although oligosymptomatic (usually cardiac) variants are reported (25,37,40,60). Heterozygous females have more variable expression due to random X chromosome inactivation, with some patients experiencing few or mild symptoms, and others developing skin, ocular, and renal manifestations, premature strokes, and myocardial infarctions, although usually later in life than affected males. Renal involvement has been recognized as a cardinal feature of Fabry disease since patients with characteristic skin lesions and albuminuria were first described in 1898 (2,17). The kidney pathology of renal involvement has been described as vacuolated epithelial cells and podocytes in the glomerulus and distal tubules (6,10). Lipid inclusions appear as clusters of intracellular vacuoles by conventional light microscopy, but exhibit dense osmiophilic staining in epon-embedded material stained with toluidine blue in epithelial cells. Electron microscopy shows intracytoplasmic irregular lamellar bodies that are lysosomes containing Gb3. With time, the glomeruli develop mesangial widening and progressive sclerosis, tubular atrophy, and interstitial fibrosis. Decreased urinary concentrating ability may be the earliest apparent renal abnormality, with onset of proteinuria in early adulthood and onset of renal failure in the fourth to fifth decades of life. Before the advent of dialysis and renal transplant, the most common cause of death was uremia, at a mean age of 41 years (11). Although there are accounts of individual patient presentations and follow-up of small kindreds, the rarity of Fabry disease has made evaluation of large groups of patients difficult to achieve. We reviewed the medical records of 105 male patients with Fabry disease. We describe the clinical course and histology of their renal disease and correlate them with residual α-gal A activity and with mutations in the α-gal A gene. Diagnosis of Fabry disease occurred later in patients without a known family history. Fifty percent of patients developed proteinuria by age 35 years and chronic renal insufficiency (CRI) by age 42 years. We found that detectable residual α-gal A activity was associated with a slower progression of Fabry renal disease, and with lower scores for renal histologic damage and renal Gb3 content. Conservative mutations in the α-gal A gene were also associated with slower progression of Fabry renal disease. Patients and Methods Definitions ( Table 1)TABLE 1: DefinitionsConditions are defined in Table 1. Hypertension was classified according to the sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (53). For patients on antihypertensive therapy, control was considered to be a systolic blood pressure ≤130 mmHg and diastolic blood pressure ≤90 mmHg. Data collection We reviewed the clinical records of 105 male Fabry patients who were evaluated at the Warren Grant Magnuson Clinical Center of the National Institutes of Health, Bethesda, Maryland, (NIH) from 1970 to 2000. All patients were enrolled in clinical protocols approved by the appropriate Institutional Review Board. The diagnosis of Fabry disease was made by the presence of the typical symptoms and signs of neuropathic pain, angiokeratoma, diarrhea and abdominal pain, proteinuria and renal failure, ocular abnormalities, or early stroke. In all patients, the clinical diagnosis was confirmed by demonstration of leukocyte α-gal A activity <15% of the value in healthy volunteers. In 49 patients, determination of leukocyte α-gal A activity was at the and in the of the patients was at Clinical the onset of clinical of Fabry disease, earliest symptoms and diagnosis of Fabry disease, blood age and cause of and and the of and urinary in a or was was usually at Data on renal and urinary from were usually to the at the of In some to of symptoms, and that were and the diagnosis of Fabry disease. Data renal tubular as urinary concentrating ability and the presence of urinary cells containing Fabry were and were in the were for of the patients who A of patients in a of α-gal A that in Patients were the for were or the on to of enzyme in the of patients who in the α-gal A the age of onset of and and of progression to proteinuria and to renal disease We the of patients a age who an was as t
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Self-citationEnzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053
Self-citationAn Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy
Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A., Kuriyama, M., Hayashibe, H., Sakuraba, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330504 · Cited by 763
Progression of diabetic nephropathy
Hovind, P., Rossing, P., Tarnow, L., Smidt, U. M., & Parving, H.-H. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002702.x · Cited by 383
Mogensen, C. E. (1976) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517609055274 · Cited by 375
Fabry, J. (1898) · Archiv für Dermatologie und Syphilis · doi:10.1007/bf01986897 · Cited by 374
An Atypical Variant of Fabry's Disease with Manifestations Confined to the Myocardium
Scheidt, W. V., Eng, C. M., Fitzmaurice, T. F., Erdmann, E., Hübner, G., Olsen, E. G. J., Christomanou, H., Kandolf, R., Bishop, D. F., & Desnick, R. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102073240607 · Cited by 371
Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.365 · Cited by 342
Self-citation
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Ries, M., & Beck, M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01309.x · Cited by 848
Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., & Wilcox, W. R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00014 · Cited by 766
Self-citationAgalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., Sims, K., Waldek, S., Pastores, G. M., Lee, P., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.013 · Cited by 544
Metadata
- Authors
- BRANTON, M. H., SCHIFFMANN, R., SABNIS, S. G., MURRAY, G. J., QUIRK, J. M., ALTARESCU, G., GOLDFARB, L., BRADY, R. O., BALOW, J. E., AUSTIN, H. A., & KOPP, J. B.
- Venue
- Medicine
- Published
- 2002-03
- Volume
- 81
- Issue
- 2
- Pages
- 122-138
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2332862830
- Cited by
- 461
- References
- 21
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course. https://app.cochat.ai/papers/10.1097/00005792-200203000-00003
- The paper
- BRANTON, M. H., SCHIFFMANN, R., SABNIS, S. G., MURRAY, G. J., QUIRK, J. M., ALTARESCU, G., GOLDFARB, L., BRADY, R. O., BALOW, J. E., AUSTIN, H. A., & KOPP, J. B. (2002). Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course. Medicine. https://doi.org/10.1097/00005792-200203000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.